Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions
Authors:
Open Access
- 1 June 2012
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 19 (11) , 22-31
Abstract
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (CRPC), a disease state now recognized to retain androgen receptor (AR)—dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting hormonal pathways in metastatic crpc. Two new drugs—the CYP17 inhibitor abiraterone acetate and the potent AR antagonist enzalutamide—were recently shown to prolong overall survival after chemotherapy treatment in patients with metastatic disease, with the former agent also demonstrating impressive activity in the pre-chemotherapy setting. Other new drugs targeting the AR—as well as drugs targeting heat shock proteins that protect cytoplasmic AR from degradation—are currently undergoing clinical development. This review brief ly describes the molecular mechanisms underlying castration resistance and hormonal dependence in prostate tumours and summarizes the current ongoing and completed clinical trials that are targeting hormonal pathways in metastatic crpc. Potential mechanisms of resistance to these novel hormonal agents are reviewed. Finally, future research directions, including questions about drug sequencing and combination, are discussed.Keywords
This publication has 46 references indexed in Scilit:
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100Cancer Research, 2012
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice VariantsClinical Cancer Research, 2011
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate CancerCancer Research, 2011
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic ResponseClinical Cancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor ActivityCancer Research, 2011
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthCancer Research, 2009
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptorBJU International, 2005
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995